Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Metabolic flexibility is the capacity to adapt fuel oxidation to fuel availability so that ATP synthesis can match its cellular demands. Thus, for example, increases in glucose availability after a meal would increase glucose oxidation, while increases in lipid availability during fasting would increase lipid oxidation. Enhanced metabolic flexibility has been proposed to protect humans from metabolic diseases. Nevertheless, most studies examining associations between metabolic flexibility and metabolic health outcomes have used cross-sectional designs. Whether impaired metabolic flexibility causes or results from metabolic health impairment is thus unclear.
In this study, the investigators will use the data from a study conducted approximately 16 years ago in healthy participants without obesity. Using the data already collected in that study, the metabolic flexibility of each participant will be calculated. To test the association between metabolic flexibility and the change in metabolic health, the investigators will call back all the participants for a single follow-up visit to reassess several metabolic health outcomes. Thus, the main aim of the study is to test the association between metabolic flexibility and the change in metabolic health outcomes after 16 years in humans.
Metabolic flexibility is the capacity to adapt fuel oxidation to fuel availability so that ATP synthesis can match its cellular demands. Thus, for example, increases in glucose availability after a meal would increase glucose oxidation, while increases in lipid availability during fasting would increase lipid oxidation. Enhanced metabolic flexibility has been proposed to protect humans from ectopic lipid accumulation and the subsequent development of insulin resistance and metabolic syndrome.
In humans, metabolic flexibility is assessed by measuring relative macronutrient oxidation (i.e., lipids and carbohydrates) in response to metabolic challenges that increase glucose or lipid availability. The respiratory exchange ratio (RER = CO2 production / O2 consumption) is used to determine relative macronutrient oxidation. The euglycemic-hyperinsulinemic clamp is a widely used challenge to assess metabolic flexibility as it increases glucose availability and thus relative glucose oxidation. Recently, other methods have been proposed to assess metabolic flexibility, including the relative lipid oxidation during an overnight fast or the difference between 24-hour RER and sleeping RER in non-exercise, energy balance conditions while staying in a metabolic chamber. The method most relevant for assessing the influence of metabolic flexibility and its effects on metabolic health outcomes is unknown.
The influence of metabolic flexibility on metabolic health outcomes remains uncertain. The lack of agreement across studies is explained by the variability in the metabolic challenges, differences in the analytical approach to compute metabolic flexibility, and the loose use of the metabolic flexibility concept in the context of many different phenomena. Moreover, most studies examining associations between metabolic flexibility and metabolic health outcomes have used cross-sectional designs. Whether impaired metabolic flexibility causes or results from metabolic health impairment is thus unclear. Longitudinal studies using well-controlled methods are required to determine the impact of metabolic flexibility on prospective metabolic health.
In this pilot and feasibility study, the investigators will use the data from a study conducted 16 years ago in 88 healthy participants without obesity (InSight study at Pennington Biomedical). The study included an euglycemic-hyperinsulinemic clamp, an overnight fasting assessment, a 24-hour stay in a metabolic chamber, and the measurement of metabolic health outcomes. Using the data already collected in the InSight study, the metabolic flexibility of each participant in the euglycemic-hyperinsulinemic clamp, the overnight fast, and the metabolic chamber will be calculated. To test the association between metabolic flexibility(ies) and the change in metabolic health outcomes, the investigators will call back all the participants for a single follow-up visit to reassess the metabolic health outcomes including body mass index, body composition, blood pressure, HOMA-IR, and the circulating concentrations of glucose, triglycerides, and cholesterol. Such data will shed light on the most informative method to assess metabolic flexibility in relationship to specific metabolic health outcomes. The investigators will use these preliminary data to design and power future projects to be submitted for funding to scientific federal agencies.
Our specific aims are to:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Insight study cohort | The proposed study will include the individuals who participated in the baseline assessment of the InSight study at Pennington Biomedical in 2008-2009. These participants were not subjected to any intervention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metabolic flexibility in the fasted state | Diagnostic Test | Measured at baseline during the InSight study (2008-2009). Calculated as the respiratory exchange ratio in the fasting state adjusted for the circulating concentrations of free fatty acids |
| Measure | Description | Time Frame |
|---|---|---|
| Glucose | Circulating concentration of glucose in mg/dL | At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
| Total cholesterol | Circulating concentration of cholesterol in mg/dL | At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
| HDL cholesterol | Circulating concentration of HDL cholesterol in mg/dL | At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
| LDL cholesterol | Circulating concentration of LDL cholesterol in mg/dL | At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
| Triglycerides | Circulating concentration of triglycerides in mg/dL | At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
| HOMA-IR | Homeostatic Model of Assessment of Insulin Resistance computed from the circulating concentrations of glucose and insulin | At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
| Blood pressure | Including systolic, diastolic, and mean blood pressure in mmHg | At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Individuals who participated in the InSight study at Pennington Biomedical in 2008-2009. Such study enrolled healthy men and women aged 20-36 years, with a body mass index <27.5 kg/m2, and a fasting glycemia <126 mg/dL.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rodrigo Fernández-Verdejo, PhD | Pennington Biomedical Research Center | Principal Investigator |
| Eric Ravussin, PhD | Pennington Biomedical Research Center | Principal Investigator |
| Leanne Redman, PhD | Pennington Biomedical Research Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pennington Biomedical Research Center | Baton Rouge | Louisiana | 70808 | United States |
The de-identified data collected will be shared upon appropriate request as part of the NORC repository of Pennington Biomedical Research Center
After publication of the results for the main outcome
Upon appropriate request
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
| Metabolic flexibility in euglycemic-hyperinsulinemic clamp | Other | Measured at baseline during the InSight study (2008-2009). Calculated as the change in respiratory exchange ratio adjusted for glucose disposal rate |
|
| Metabolic flexibility in the metabolic chamber | Other | Measured at baseline during the InSight study (2008-2009). Calculated as the difference between awake respiratory exchange ratio (from 8 a.m. to 11 p.m.) and sleeping respiratory exchange ratio during a 23-hour stay in the metabolic chamber |
|
| Waist circumference |
Measured in cm |
| At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
| Body mass index | Calculated from the ratio between the weight and height, and expressed in kg/m2 | At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
| Body fat percentage | Measured by DXA and expressed as percentage of body weight | At baseline (in 2008-2009) and after approximately 16 years (2024-2025) |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |